JP2004517045A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004517045A5 JP2004517045A5 JP2002521491A JP2002521491A JP2004517045A5 JP 2004517045 A5 JP2004517045 A5 JP 2004517045A5 JP 2002521491 A JP2002521491 A JP 2002521491A JP 2002521491 A JP2002521491 A JP 2002521491A JP 2004517045 A5 JP2004517045 A5 JP 2004517045A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- betulinic acid
- cancer
- hydrogen
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 description 19
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 11
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 8
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 8
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 8
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 150000002431 hydrogen Chemical class 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 0 CC(C)([C@@](CC1)[C@](C)(CC2)[C@@](CC3)[C@]1(C)[C@@]1(C)[C@]3[C@@]([C@@](CC3)C(CO)=C)[C@@]3(*)CC1)[C@]2O Chemical compound CC(C)([C@@](CC1)[C@](C)(CC2)[C@@](CC3)[C@]1(C)[C@@]1(C)[C@]3[C@@]([C@@](CC3)C(CO)=C)[C@@]3(*)CC1)[C@]2O 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22653600P | 2000-08-18 | 2000-08-18 | |
| PCT/US2001/025581 WO2002016395A1 (en) | 2000-08-18 | 2001-08-15 | Prodrugs of betulinic acid derivatives for the treatment of cancer and hiv |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004517045A JP2004517045A (ja) | 2004-06-10 |
| JP2004517045A5 true JP2004517045A5 (enExample) | 2008-10-02 |
Family
ID=22849310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002521491A Pending JP2004517045A (ja) | 2000-08-18 | 2001-08-15 | 癌およびｈｉｖの治療用ベツリン酸誘導体のプロドラッグ |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US6569842B2 (enExample) |
| EP (1) | EP1309605A1 (enExample) |
| JP (1) | JP2004517045A (enExample) |
| AU (2) | AU2001284946B2 (enExample) |
| CA (1) | CA2418479C (enExample) |
| NO (1) | NO20030748L (enExample) |
| NZ (1) | NZ524087A (enExample) |
| WO (1) | WO2002016395A1 (enExample) |
| ZA (1) | ZA200301269B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6943260B2 (en) * | 2002-02-02 | 2005-09-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for obtaining betulinic acid |
| ATE350383T1 (de) * | 2002-08-23 | 2007-01-15 | Sloan Kettering Inst Cancer | Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen |
| US7365221B2 (en) | 2002-09-26 | 2008-04-29 | Panacos Pharmaceuticals, Inc. | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| EP1594885B8 (de) * | 2003-02-11 | 2009-03-25 | Novelix Pharmaceuticals, Inc. | Medikament zur wachstumsinhibierung von tumoren |
| AU2004224053B2 (en) | 2003-03-24 | 2011-06-09 | Sterix Limited | Oestrogen derivatives as inhibitors of steroid sulphatase |
| WO2005046575A2 (en) * | 2003-07-29 | 2005-05-26 | Signature R & D Holdings, Lcc | Amino acid prodrugs |
| WO2005112929A2 (en) * | 2004-05-20 | 2005-12-01 | Cornell Research Foundation, Inc. | Anti-hiv-1 activity of betulinol derivatives |
| ES2575871T3 (es) * | 2004-08-02 | 2016-07-01 | Ambrilia Biopharma Inc. | Composiciones farmacéuticas que comprende un compuesto a base de lisina y un agente antiviral o antirretroviral VIH |
| US20060154904A1 (en) * | 2004-09-10 | 2006-07-13 | Cornell Research Foundation, Inc. | Betulinol derivatives as anti-HIV agents |
| AR051475A1 (es) * | 2004-11-05 | 2007-01-17 | Merck & Co Inc | Procedimiento para acido{3- [2 (r) -[(1r) - 1-[ 3,5- bis( trifluorometil)- fenil] etoxi] -3 (s) - (4- fluorfenil) morfolin -4- il]metil -5-oxo-4,5-dihidro- [1,2,4]-triazol-1-il} fosfonico |
| JP4810642B2 (ja) * | 2004-11-30 | 2011-11-09 | 秋田県 | 癌転移抑制用トリテルペン誘導体及び該トリテルペン誘導体を用いた癌転移抑制用組成物 |
| EP1869063A2 (en) * | 2005-03-29 | 2007-12-26 | Regents Of The University Of Minnesota | Methods of manufacturing bioactive 3-esters of betulinic aldehyde and betulinic acid |
| US20070111936A1 (en) | 2005-11-15 | 2007-05-17 | Vladimir Pak | Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer |
| AU2006333084A1 (en) * | 2005-12-16 | 2007-07-12 | Panacos Pharmaceuticals, Inc. | Preparation of pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid |
| GB0604535D0 (en) * | 2006-03-07 | 2006-04-12 | Sndv Sprl | Betulonic acid derivatives |
| US20110152229A1 (en) * | 2006-11-22 | 2011-06-23 | Duke University | Betulinic acid derivatives as anti-hiv agents |
| US20090062243A1 (en) * | 2007-08-03 | 2009-03-05 | Advanced Life Sciences, Inc. | Lupane-Type Triterpenoids Modified at 30-Position and Analogues Thereof |
| EP2371368A3 (en) * | 2008-05-30 | 2012-08-22 | Novelix Pharmaceuticals, Inc. | Compositions and methods for treatment of inflammation and hyperkeratotic lesions |
| US8372808B2 (en) * | 2008-10-31 | 2013-02-12 | Wisconsin Alumni Research Foundation | Suppression of glial fibrillary acidic protein |
| WO2010068668A1 (en) * | 2008-12-10 | 2010-06-17 | Advanced Life Sciences, Inc. | 23-substituted derivatives of lupane-type pentacyclic triterpenoids |
| RU2551647C2 (ru) * | 2012-11-12 | 2015-05-27 | Федеральное государственное бюджетное учреждение науки Институт нефтехимии и катализа Российской академии наук | Трифенилфосфониевые соли лупановых тритерпеноидов, способ получения и применение в качестве противоопухолевых веществ |
| KR101531821B1 (ko) * | 2013-11-27 | 2015-06-24 | 주식회사 휴메딕스 | 페길레이션된 베튤린 유도체를 포함하는 경구 투여용 항암제 조성물 |
| CN107011406A (zh) * | 2016-01-28 | 2017-08-04 | 思路迪（北京）医药科技有限公司 | 一种具有抗肿瘤作用的化合物及其制备方法和应用 |
| AU2018334467B2 (en) | 2017-09-14 | 2022-10-20 | Phoenix Biotechnology, Inc. | Method and improved neuroprotective composition for treating neurological conditions |
| AU2018334386B2 (en) | 2017-09-14 | 2021-11-04 | Phoenix Biotechnology, Inc. | Method and composition for treating viral infection |
| NZ769842A (en) | 2018-06-29 | 2023-01-27 | Dfh Therapeutics | Triterpene amine derivatives |
| WO2020124043A1 (en) * | 2018-12-13 | 2020-06-18 | Gordon Erlinda M | Methods of exploiting oncogenic drivers along the human cyclin g1 pathway for cancer gene therapy |
| KR102464428B1 (ko) | 2020-03-31 | 2022-11-04 | 피닉스 바이오테크놀러지 인코포레이티드. | 코로나바이러스 감염 치료를 위한 방법 및 조성물 |
| EP4295854A3 (en) | 2020-03-31 | 2024-04-03 | Phoenix Biotechnology, Inc. | Method and compositions for treating coronavirus infection |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2683531B1 (fr) * | 1991-11-13 | 1993-12-31 | Rhone Poulenc Rorer Sa | Nouveaux derives du lupane, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2705097B1 (fr) * | 1993-05-11 | 1995-08-04 | Rhone Poulenc Rorer Sa | Nouveaux dérivés du lupane, leur préparation et les compositions pharmaceutiques qui les contiennent. |
| US5658947A (en) | 1995-03-21 | 1997-08-19 | Board Of Trustees Of The University Of Illinois | Method and composition for selectively inhibiting melanoma using betalinic acid |
| US5962527A (en) | 1995-03-21 | 1999-10-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for treating cancers |
| US5869535A (en) | 1995-03-21 | 1999-02-09 | The Board Of Trustees Of The University Of Illinois | Method and composition for selectively inhibiting melanoma |
| JPH0987156A (ja) * | 1995-09-19 | 1997-03-31 | Pola Chem Ind Inc | 光老化防止剤及び皮膚化粧料 |
| US5804575A (en) | 1997-03-27 | 1998-09-08 | The Board Of Trustees Of The University Of Illinois | Methods of manufacturing betulinic acid |
| US6048847A (en) * | 1997-09-30 | 2000-04-11 | Dabur Research Foundation | Use of betulinic acid and its derivatives for inhibiting cancer growth and a method of monitoring this |
| US6670345B1 (en) * | 1997-09-30 | 2003-12-30 | Dabur Research Foundation | Betulinic acid derivatives for inhabiting cancer growth and process for the manufacture of betulinic acid |
| EP0943620B1 (en) * | 1998-03-18 | 2005-11-16 | Dabur Pharma Ltd. | Betulinic acid derivatives for inhibiting cancer growth |
| ATE420889T1 (de) | 1998-11-18 | 2009-01-15 | Dabur Pharma Ltd | Betulinsäurederivate zur inhibierung des krebswachstums und ein verfahren zu ihrer herstellung |
| CA2366807A1 (en) * | 1999-04-07 | 2000-10-12 | Washington State University Research Foundation | Anti-tumor activity of vitamin e, cholesterol, taxol and betulinic acid derivatives |
| EP1321145A4 (en) * | 2000-07-31 | 2006-03-22 | Nisshin Oillio Ltd | ANTITUMOR SUBSTANCES |
-
2001
- 2001-08-15 JP JP2002521491A patent/JP2004517045A/ja active Pending
- 2001-08-15 AU AU2001284946A patent/AU2001284946B2/en not_active Ceased
- 2001-08-15 EP EP01964047A patent/EP1309605A1/en not_active Ceased
- 2001-08-15 CA CA002418479A patent/CA2418479C/en not_active Expired - Fee Related
- 2001-08-15 WO PCT/US2001/025581 patent/WO2002016395A1/en not_active Ceased
- 2001-08-15 AU AU8494601A patent/AU8494601A/xx active Pending
- 2001-08-15 NZ NZ524087A patent/NZ524087A/en unknown
- 2001-08-15 US US09/930,656 patent/US6569842B2/en not_active Expired - Fee Related
-
2003
- 2003-01-13 US US10/340,934 patent/US7091195B2/en not_active Expired - Fee Related
- 2003-02-17 ZA ZA200301269A patent/ZA200301269B/xx unknown
- 2003-02-17 NO NO20030748A patent/NO20030748L/no not_active Application Discontinuation
-
2006
- 2006-06-28 US US11/477,177 patent/US20070072835A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004517045A5 (enExample) | ||
| CN103313992B (zh) | 具有hdac抑制作用的喜树碱衍生物 | |
| JP2022121594A5 (enExample) | ||
| JP2004514663A5 (enExample) | ||
| ES2522971T3 (es) | Nuevo derivado de la prostaglandina I2 | |
| JP2017537126A5 (enExample) | ||
| JP2003509349A5 (enExample) | ||
| JP2008528671A5 (enExample) | ||
| JP2009536191A5 (enExample) | ||
| RU2009102243A (ru) | Производные камптотецина с противоопухолевой активностью | |
| JP2021147340A (ja) | 化合物、そのナノ粒子及び癌疾患の治療剤 | |
| CN110461836B (zh) | 一种选择性抑制激酶化合物及其用途 | |
| JP5819523B2 (ja) | カンプトテシン誘導体とその製造方法、医薬組成物とその用途 | |
| JP2004517882A (ja) | トリプトライドプロドラッグを使用する抗癌処置 | |
| JP7732678B2 (ja) | リン酸塩誘導体およびその用途 | |
| JP2019513812A5 (enExample) | ||
| JP2014534268A5 (enExample) | ||
| JP2002510667A5 (enExample) | ||
| JP2007532649A5 (enExample) | ||
| JPWO2021093839A5 (enExample) | ||
| JP2003505513A5 (enExample) | ||
| JP2013525290A5 (enExample) | ||
| CN101775032A (zh) | 氯硝柳胺磷酸酯、其药学上可接受的盐及其应用 | |
| JP2010500971A5 (enExample) | ||
| RU2010120810A (ru) | Гидратированные кристаллические сложные эфиры камптотецина для лечения рака |